HCW Biologics Inc. (HCWB) - Dilution Analysis

8-K filing: HCW Biologics Inc. issued and sold 427,046 shares of common stock, 2,419,929 pre-funded warrants, and 2,846,975 common warrants for aggregate gross proceeds of approximately $4 million. ($4.0M proceeds)

10-Q filing | 6.7M shares outstanding

POS AM filing: The company is offering up to $5.6 million of common stock or pre-funded warrants on a reasonable best efforts basis.

S-1/A filing: HCW Biologics Inc. is offering up to 13,625,304 shares of common stock or pre-funded warrants to purchase up to 13,625,304 shares of common stock, for gross proceeds of approximately $5.6 million.

S-1 filing: This S-1 filing, dated April 23, 2026, relates to a proposed offering of up to $5,600,000 of common stock or pre-funded warrants.

10-K filing | 6.7M shares outstanding

S-1 filing: This prospectus relates to the proposed resale by the respective selling stockholders identified below of up to 3,400,033 shares of our Common Stock, which are issuable upon exercise of the Conversion Shares, Conversion Warrants and New Warrants.

8-K filing: HCW Biologics Inc. entered into an inducement offer agreement with an institutional investor, resulting in the exercise of existing warrants and the issuance of new warrants, with gross proceeds of approximately $4.0 million. ($4.0M proceeds)

10-Q filing | 2.7M shares outstanding

8-K filing: Armistice Capital Master Fund Ltd. exercised pre-funded warrants to purchase 54,000 shares of HCW Biologics Inc. common stock on June 18, 2025, completing the full exercise of the pre-funded warrants.

8-K filing: HCW Biologics Inc. reports that Armistice Capital Master Fund Ltd. exercised pre-funded warrants to purchase 85,000 shares of the Company's common stock on June 12, 2025, and continues to hold pre-funded warrants that may be exercised for 54,000 shares of common stock.

8-K filing: HCW Biologics Inc. issued 71,000 shares of common stock to Armistice Capital Master Fund Ltd. on May 29, 2025, as a result of the exercise of pre-funded warrants, with Armistice retaining pre-funded warrants to purchase up to 139,000 additional shares.

8-K filing: HCW Biologics Inc. issued 126,000 shares of registered Common Stock to Armistice Capital Master Fund Ltd. on May 22, 2025, following the exercise of some of its Pre-Funded Warrants.

8-K filing: HCW Biologics Inc. issued 177,140 shares of common stock to Armistice Capital Master Fund Ltd. upon exercise of pre-funded warrants, and issued 8,054 shares to Hing C. Wong, 13,423 shares to Scott T. Garrett, and 1,342 shares to Gary M. Winer upon conversion of Convertible Bridge Notes.

8-K filing: HCW Biologics Inc. completed a follow-on public offering of 158,000 shares of common stock, pre-funded warrants to purchase up to 513,140 shares, and warrants to purchase up to 1,342,280 shares for gross proceeds of approximately $5.0 million. ($15.0M proceeds)

10-Q filing | 1.4M shares outstanding

S-1/A filing: HCW Biologics Inc. files an S-1/A registration statement relating to the offering and sale of up to $5,000,000 of Units each consisting of (a)(i) one share of Common Stock or (ii) one Pre-Funded Warrant to purchase one share of Common Stock; and (b) two common stock purchase warrants to purchase up to an aggregate of $10,000,000 of shares of Common Stock.

S-1 filing: HCW Biologics Inc. is offering up to 655,308 units, each consisting of one share of common stock and two common stock warrants, as well as pre-funded warrants for certain investors, for gross proceeds of approximately $5,000,000, with the intention of using the proceeds for clinical development, research and development costs, business development, patent portfolio expansion, studies for publications, and general corporate purposes.

8-K filing: Stock split 1-for-40 | Outstanding: 44,934,120 → 1,123,353

S-1 filing: This prospectus relates to the proposed resale by the respective selling stockholders identified below of up to the following respective amounts of shares of our common stock, par value $0.0001 per share.

10-K filing | 44.9M shares outstanding

8-K filing: HCW Biologics Inc. issued 2,557,000 shares of registered common stock to Armistice Capital Master Fund Ltd. on November 21, 2024, following the exercise of pre-funded warrants.

8-K filing: HCW Biologics Inc. completed a registered direct offering and concurrent private placement on November 20, 2024, selling 4,160,000 shares of common stock and pre-funded warrants to purchase 2,557,000 shares, along with unregistered warrants to purchase 6,717,000 shares of common stock, for gross proceeds of approximately $6.9 million.

10-Q filing | 35.9M shares outstanding

10-Q filing | 35.9M shares outstanding

10-Q filing | 35.9M shares outstanding

10-K filing | 35.8M shares outstanding

8-K filing: HCW Biologics Inc. sold 1,785,718 shares of its common stock to certain officers and directors at a purchase price of $1.40 per share for an aggregate purchase price of $2.5 million. ($2.5M proceeds)

10-Q filing | 35.8M shares outstanding

10-Q filing | 35.8M shares outstanding

10-Q filing | 35.8M shares outstanding

10-K filing | 35.9M shares outstanding

10-Q filing | 35.9M shares outstanding

S-3 filing: HCW Biologics Inc. may offer up to $100 million aggregate dollar amount of common stock or preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, subscription rights to purchase common stock, preferred stock or debt securities and/or units consisting of some or all of these securities.

10-Q filing | 35.8M shares outstanding

10-Q filing | 35.8M shares outstanding

10-K filing | 35.8M shares outstanding

10-Q filing | 35.7M shares outstanding

10-Q filing | 35.7M shares outstanding

S-1/A filing: This S-1/A filing details an offering of common stock underwritten by EF Hutton, with an over-allotment option, including discounts and commissions information.

S-1/A filing: This is an S-1/A filing for an offering of common stock underwritten by EF Hutton, with an over-allotment option.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock with an over-allotment option.